Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Decrease in Short Interest

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 75,400 shares, a decrease of 7.8% from the May 31st total of 81,800 shares. Based on an average daily volume of 653,500 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Oppenheimer raised Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 16th.

Avalo Therapeutics Stock Down 5.5 %

Shares of AVTX opened at $12.47 on Monday. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $96.14. The business’s 50 day simple moving average is $12.33 and its 200-day simple moving average is $9.57.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($5.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($4.80). Avalo Therapeutics had a negative return on equity of 1,439.87% and a negative net margin of 1,639.50%. Research analysts predict that Avalo Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in Avalo Therapeutics during the 3rd quarter valued at $34,000. Affinity Asset Advisors LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth approximately $218,000. Finally, Ikarian Capital LLC purchased a new position in Avalo Therapeutics during the 1st quarter valued at $1,015,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.